|
Jul 18
|
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
|
|
Jul 17
|
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
|
|
Jul 10
|
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
|
|
Jul 10
|
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
|
|
Jun 11
|
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
|
|
Jun 10
|
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
|
|
Jun 9
|
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting
|
|
Jun 9
|
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
|
|
Jun 9
|
Keros Announces Return of $375 Million in Excess Capital to Stockholders
|
|
Feb 28
|
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
|
|
Feb 26
|
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 26
|
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
|
|
Jan 30
|
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
|
|
Jan 28
|
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
|
|
Sep 12
|
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
|
|
Aug 7
|
Keros Therapeutics Reports Second Quarter 2024 Financial Results
|
|
Jun 17
|
Keros Therapeutics Announces Leadership Updates
|
|
Jun 17
|
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
|
|
May 14
|
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
|
|
May 10
|
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
|